Unraveling the Dark Matter, Long Non-coding RNAs, in Male Reproductive Diseases: A Narrative Review

Overview

Journal Int J Reprod Biomed

Specialty Reproductive Medicine

Date 2020 Dec 22

PMID 33349800

Authors

Masoud Dehghan Tezerjani

Seyed Mehdi Kalantar

Affiliations

Soon will be listed here.

Abstract

Recent advances in human transcriptome have revealed the fundamental and functional roles of long non-coding RNA in the susceptibility to diverse diseases and pathological conditions. They participate in wide range of biological processes such as the modulating of chromatin structure, transcription, translation, and post-translation modification. In addition, based on their unique expression profiles and their association with clinical abnormalities such as those of related to male reproductive diseases, they can be used to develop therapeutic methods and biomarkers for screening of the diseases. In this study, we will review the identified lncRNAs and their molecular functions in the pathogenesis of male reproductive diseases such as prostate cancer, benign prostatic hyperplasia, prostatitis, testicular cancer, varicocele, and sperm abnormalities.

References

Khalil A, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D . Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A. 2009; 106(28):11667-72. PMC: 2704857. DOI: 10.1073/pnas.0904715106. View

Arunkumar G, Anand S, Raksha P, Dhamodharan S, Prasanna Srinivasa Rao H, Subbiah S . LncRNA OIP5-AS1 is overexpressed in undifferentiated oral tumors and integrated analysis identifies as a downstream effector of stemness-associated transcription factors. Sci Rep. 2018; 8(1):7018. PMC: 5935738. DOI: 10.1038/s41598-018-25451-3. View

Bokhorst L, Bangma C, van Leenders G, Lous J, Moss S, Schroder F . Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 2013; 65(2):329-36. DOI: 10.1016/j.eururo.2013.08.005. View

Chen Q, Sun T, Wang F, Gong B, Xie W, Ma M . Long Noncoding RNA IGF2AS is Acting as an Epigenetic Tumor Suppressor in Human Prostate Cancer. Urology. 2018; 124:310.e1-310.e8. DOI: 10.1016/j.urology.2018.11.002. View

Orfanelli U, Jachetti E, Chiacchiera F, Grioni M, Brambilla P, Briganti A . Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer. Oncogene. 2014; 34(16):2094-102. DOI: 10.1038/onc.2014.144. View

Zhang X, Gao F, Fu J, Zhang P, Wang Y, Zeng X . Systematic identification and characterization of long non-coding RNAs in mouse mature sperm. PLoS One. 2017; 12(3):e0173402. PMC: 5349675. DOI: 10.1371/journal.pone.0173402. View

Xue D, Zhou C, Lu H, Xu R, Xu X, He X . LncRNA GAS5 inhibits proliferation and progression of prostate cancer by targeting miR-103 through AKT/mTOR signaling pathway. Tumour Biol. 2016; 37:16187–16197. DOI: 10.1007/s13277-016-5429-8. View

Lavorgna G, Chiacchiera F, Briganti A, Montorsi F, Pasini D, Salonia A . Expression-profiling of apoptosis induced by ablation of the long ncRNA TRPM2-AS in prostate cancer cell. Genom Data. 2015; 3:4-5. PMC: 4535459. DOI: 10.1016/j.gdata.2014.10.020. View

Li J, Liu F, Zhang B, Bai W, Cheng W, Zhang Y . LncRNA625 modulates prostate cancer cells proliferation and apoptosis through regulating the Wnt/β-catenin pathway by targeting miR-432. Eur Rev Med Pharmacol Sci. 2017; 21(11):2586-2595. View

10.

Fretz P, Sandlow J . Varicocele: current concepts in pathophysiology, diagnosis, and treatment. Urol Clin North Am. 2003; 29(4):921-37. DOI: 10.1016/s0094-0143(02)00075-7. View

11.

Beaver L, Kuintzle R, Buchanan A, Wiley M, Glasser S, Wong C . Long noncoding RNAs and sulforaphane: a target for chemoprevention and suppression of prostate cancer. J Nutr Biochem. 2017; 42:72-83. PMC: 5360475. DOI: 10.1016/j.jnutbio.2017.01.001. View

12.

Zhang G, Han G, Zhang X, Yu Q, Li Z, Li Z . Long non-coding RNA FENDRR reduces prostate cancer malignancy by competitively binding miR-18a-5p with RUNX1. Biomarkers. 2018; 23(5):435-445. DOI: 10.1080/1354750X.2018.1443509. View

13.

Misawa A, Takayama K, Urano T, Inoue S . Androgen-induced Long Noncoding RNA (lncRNA) SOCS2-AS1 Promotes Cell Growth and Inhibits Apoptosis in Prostate Cancer Cells. J Biol Chem. 2016; 291(34):17861-80. PMC: 5016176. DOI: 10.1074/jbc.M116.718536. View

14.

Hangauer M, Vaughn I, McManus M . Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. PLoS Genet. 2013; 9(6):e1003569. PMC: 3688513. DOI: 10.1371/journal.pgen.1003569. View

15.

Zhao R, Sun F, Bei X, Wang X, Zhu Y, Jiang C . Upregulation of the long non-coding RNA FALEC promotes proliferation and migration of prostate cancer cell lines and predicts prognosis of PCa patients. Prostate. 2017; 77(10):1107-1117. DOI: 10.1002/pros.23367. View

16.

Lemos A, Ferreira L, Batoreu N, de Freitas P, Bonamino M, Gimba E . PCA3 long noncoding RNA modulates the expression of key cancer-related genes in LNCaP prostate cancer cells. Tumour Biol. 2016; 37(8):11339-48. DOI: 10.1007/s13277-016-5012-3. View

17.

Zhao J, Li H, Deng H, Zhu L, Zhou B, Yang M . LncRNA gadd7, increased in varicocele patients, suppresses cell proliferation and promotes cell apoptosis. Oncotarget. 2018; 9(4):5105-5110. PMC: 5797036. DOI: 10.18632/oncotarget.23696. View

18.

McVary K . BPH: epidemiology and comorbidities. Am J Manag Care. 2006; 12(5 Suppl):S122-8. View

19.

Wang J, Yang X, Li R, Wang L, Gu Y, Zhao Y . Long non-coding RNA MYU promotes prostate cancer proliferation by mediating the miR-184/c-Myc axis. Oncol Rep. 2018; 40(5):2814-2825. DOI: 10.3892/or.2018.6661. View

20.

Cooper T, Noonan E, von Eckardstein S, Auger J, Baker H, Behre H . World Health Organization reference values for human semen characteristics. Hum Reprod Update. 2009; 16(3):231-45. DOI: 10.1093/humupd/dmp048. View